Cargando…
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
BACKGROUND: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). METHODS: OAT prescriptions were required monthly at one...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474458/ https://www.ncbi.nlm.nih.gov/pubmed/37663576 http://dx.doi.org/10.1016/j.jve.2023.100338 |
_version_ | 1785100498262556672 |
---|---|
author | Schwarz, Caroline Schubert, Raphael Schwarz, Michael Schütz, Angelika Jenke, Anika Bauer, David Steinwender, Benjamin Gutic, Enisa Reiberger, Thomas Haltmayer, Hans Gschwantler, Michael |
author_facet | Schwarz, Caroline Schubert, Raphael Schwarz, Michael Schütz, Angelika Jenke, Anika Bauer, David Steinwender, Benjamin Gutic, Enisa Reiberger, Thomas Haltmayer, Hans Gschwantler, Michael |
author_sort | Schwarz, Caroline |
collection | PubMed |
description | BACKGROUND: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). METHODS: OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed. RESULTS: 4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred. CONCLUSION: Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs. |
format | Online Article Text |
id | pubmed-10474458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104744582023-09-03 CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers Schwarz, Caroline Schubert, Raphael Schwarz, Michael Schütz, Angelika Jenke, Anika Bauer, David Steinwender, Benjamin Gutic, Enisa Reiberger, Thomas Haltmayer, Hans Gschwantler, Michael J Virus Erad Original Research BACKGROUND: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). METHODS: OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed. RESULTS: 4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred. CONCLUSION: Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs. Elsevier 2023-07-27 /pmc/articles/PMC10474458/ /pubmed/37663576 http://dx.doi.org/10.1016/j.jve.2023.100338 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Schwarz, Caroline Schubert, Raphael Schwarz, Michael Schütz, Angelika Jenke, Anika Bauer, David Steinwender, Benjamin Gutic, Enisa Reiberger, Thomas Haltmayer, Hans Gschwantler, Michael CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers |
title | CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers |
title_full | CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers |
title_fullStr | CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers |
title_full_unstemmed | CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers |
title_short | CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers |
title_sort | chime - a tailored hcv microelimination project in viennese people who inject drugs at drug centralized substitution centers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474458/ https://www.ncbi.nlm.nih.gov/pubmed/37663576 http://dx.doi.org/10.1016/j.jve.2023.100338 |
work_keys_str_mv | AT schwarzcaroline chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT schubertraphael chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT schwarzmichael chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT schutzangelika chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT jenkeanika chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT bauerdavid chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT steinwenderbenjamin chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT guticenisa chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT reibergerthomas chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT haltmayerhans chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters AT gschwantlermichael chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters |